Genetic markers predictive of response to glatiramer acetate

A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:

• (i) determining the genotype of the subject at a single nucleotide polymorphism (SNP) kgp7747883;
• (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more G alleles at the location of kgp7747883;
• and
• (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

A method of identifying a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis as a predicted responder or as a predicted non-responder to glatiramer acetate, the method comprising the steps of:

• (i) determining using a probe or primer the genotype of the subject at single nucleotide polymorphism (SNP) kgp7747883 and
• (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains
• one or more G alleles at the location of kgp7747883;
• or
• identifying the human subject as a predicted non-responder to glatiramer acetate if the genotype of the subject contains
• no G alleles at the location of kgp7747883,
• thereby identifying a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis as a predicted responder or as a predicted non-responder to glatiramer acetate.